Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

September 19, 2007 09:29 ET

Mistral Pharma to Hold Annual General Meeting of Shareholders on September 20, 2007

MONTREAL, QUEBEC--(Marketwire - Sept. 19, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") announced today that it will host its 2007 Annual General Meeting of Shareholders for its fiscal year ended March 31, 2007 on Thursday, September 20 2007. The meeting will be held at 2:00 pm, in the Salon Rubis of the Holiday Inn, 6500 Cote de Liesse, Montreal, Quebec.

About Mistral Pharma Inc.

Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02 & MIST-B03, showed positive results at their respective first pilot clinical trials. Mistral also has the Canadian rights to Instillagel®, a local anesthetic and antiseptic combination product used for urology procedures which is expected to be launched in Canada during Q4 2007. Mistral positions itself as a development and marketing partner for pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    514-421-1717 # 2224
    bbolduc@mistralpharma.com
    or
    Mistral Pharma Inc.
    Alain Provencher, CA, CF
    Vice-president, Finance & Chief Financial Officer
    514-421-1717 # 2222
    aprovencher@mistralpharma.com